

Resource Summary Report

Generated by PRECISE-TBI on Aug 31, 2026

FAK (D2R2E) Rabbit mAb

RRID:AB_2798086

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 13009, RRID:AB_2798086

Antibody Information

URL: http://antibodyregistry.org/AB_2798086

Proper Citation: Cell Signaling Technology Cat# 13009, RRID:AB_2798086

Target Antigen: FAK

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP

Antibody Name: FAK (D2R2E) Rabbit mAb

Description: This monoclonal targets FAK

Target Organism: h, m

Clone ID: Clone D2R2E

Antibody ID: AB_2798086

Vendor: Cell Signaling Technology

Catalog Number: 13009

Record Creation Time: 20250819T235329+0000

Record Last Update: 20250820T064412+0000

Ratings and Alerts

No rating or validation information has been found for FAK (D2R2E) Rabbit mAb.

No alerts have been found for FAK (D2R2E) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 22 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

An K, et al. (2026) Hypoxia-activated PROTAC for dual inhibition of FAK and EGFR enables synergistic mechano-chemical cancer therapy. *Neoplasia* (New York, N.Y.), 79, 101328.

Govindarajan M, et al. (2026) Pan-cancer N-glycoproteomic atlas of patient-derived xenografts uncovers FAT2 as an actionable surface target. *Cell reports. Medicine*, 7(2), 102578.

Papaioannou G, et al. (2026) Regulation of cAMP levels in osteocytes by mechano-sensitive focal adhesion kinase and phosphodiesterase 8A. *iScience*, 29(6), 116049.

Lee SH, et al. (2025) Dynamic decoding of VEGF signaling and coordinated control of multiple phenotypes by the Src-TEM4-YAP pathway. *Cell systems*, 16(7), 101321.

Kopietz F, et al. (2025) Focal Adhesion Kinase Orchestrates GLUT4 Translocation and Glucose Uptake via Cytoskeletal Turnover in Primary Adipocytes. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 39(10), e70660.

Mulkearns-Hubert EE, et al. (2024) Targeting NANOG and FAK via Cx26-derived Cell-penetrating Peptides in Triple-negative Breast Cancer. *Molecular cancer therapeutics*, 23(1), 56.

Girnius N, et al. (2024) Cilengitide sensitivity is predicted by overall integrin expression in breast cancer. *Breast cancer research : BCR*, 26(1), 187.

Zhang H, et al. (2024) The extracellular matrix integrates mitochondrial homeostasis. *Cell*, 187(16), 4289.

Liu Y, et al. (2024) Sarcoma Cells Secrete Hypoxia-Modified Collagen VI to Weaken the Lung Endothelial Barrier and Promote Metastasis. *Cancer research*, 84(7), 977.

Jeon HM, et al. (2023) Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling. *Cancer cell*, 41(8), 1480.

Lee YJ, et al. (2023) GPR143 controls ESCRT-dependent exosome biogenesis and promotes cancer metastasis. *Developmental cell*, 58(4), 320.

Rizza S, et al. (2023) GSNOR deficiency promotes tumor growth via FAK1 S-nitrosylation. *Cell reports*, 42(1), 111997.

Shiraishi K, et al. (2023) Biophysical forces mediated by respiration maintain lung alveolar epithelial cell fate. *Cell*, 186(7), 1478.

He D, et al. (2022) Methionine oxidation activates pyruvate kinase M2 to promote pancreatic cancer metastasis. *Molecular cell*, 82(16), 3045.

Tiberti M, et al. (2022) The Cancermuts software package for the prioritization of missense cancer variants: a case study of AMBRA1 in melanoma. *Cell death & disease*, 13(10), 872.

Remsing Rix LL, et al. (2022) IGF-binding proteins secreted by cancer-associated fibroblasts induce context-dependent drug sensitization of lung cancer cells. *Science signaling*, 15(747), eabj5879.

Liu CL, et al. (2022) CRABP2 Is Associated With Thyroid Cancer Recurrence and Promotes Invasion via the Integrin/FAK/AKT Pathway. *Endocrinology*, 163(12).

Marin-Bejar O, et al. (2021) Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma. *Cancer cell*, 39(8), 1135.

O'Donohue TJ, et al. (2021) Translational Strategies for Repotrectinib in Neuroblastoma. *Molecular cancer therapeutics*, 20(11), 2189.

Gasca J, et al. (2020) EDIL3 promotes epithelial-mesenchymal transition and paclitaxel resistance through its interaction with integrin $\alpha 3$ in cancer cells. *Cell death discovery*, 6, 86.